In article <
[email protected]>,
Roger Schlafly <
[email protected]> wrote:
>"JG" <
[email protected]> wrote
>> I agree. There's *nothing* to indicate that the users weren't addicted, and, while the fact they
>> (all!) chose to continue taking it isn't proof of addiction, it, at least, can be used to support
>> that conclusion.
>
>Mark can read just about any ritalin study, and conclude that it shows that ritalin is not
>addictive. Well, it doesn't show that. All the studies are consistent with the notion that ritalin
>is addictive.
Oh, no they aren't -- not when it's taken orally, which is what was being done in the study under
discussion. Here are a couple of nice references for you:
Tidsskr Nor Laegeforen. 1999 Nov 10;119(27):4040-2. Related Articles, Links
[Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders]
[Article in Norwegian]
Aanonsen NO.
Avdeling for voksenhabilitering Ulleval sykehus, Oslo.
[email protected]
The literature on the medical use of methylphenidate for hyperkinetic disorder/AD/HD does not
support that its use implies a substantial risk for substance abuse, serious complications or drug
dependence. Recent pharmacokinetic studies with PET throw light on the empirical findings of low
rate of abuse, as the euforigenic potential of methylphenidate taken orally appears to be very
modest. Methylphenidate should be the drug of choice in the treatment of adults with hyperkinetic
disorder/AD/HD. However, current substance abuse precludes use of the drug and former abuse
liability and social adjustment problems are relative contraindications. There is a lack of
scientific data on the use of dextroamphetamine in adults with hyperkinetic disorder/AD/HD. The
drug has a higher potential for abuse than methylphenidate and should be considered as a second
choice only after an individual consideration of compliance and if methylphenidate proves
ineffective. Rigid control of the prescription is necessary, and a medical history of substance
abuse should in our opinion preclude its use.
and
J Atten Disord. 2002;6 Suppl 1:S65-71. Related Articles, Links
Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies.
Huss M, Lehmkuhl U.
Department of Child and Adolescent Psychiatry, Charite Virchow-Hospital, Humboldt-University of
Berlin, Germany.
[email protected]
This article reviews pharmacological, animal, and human evidence regarding the abuse liability of
methylphenidate (MPH). Findings are not always consistent, but evidence converges to suggest that
although intravenous methylphenidate has some abuse potential, there is very little potential for
oral MPH abuse. Furthermore, the available data suggests that children with Attention-
Deficit/Hyperactivity Disorder (ADHD) who are treated with MPH are at lower risk for substance use
disorder later in life. More longitudinal, prospective studies are needed to assess the long term
effects of MPH treatment in ADHD.
-- David Wright :: alphabeta at prodigy.net These are my opinions only, but they're almost always
correct. "If I have not seen as far as others, it is because giants were standing on my
shoulders." (Hal Abelson, MIT)